PHFA announces PHARE funding for nearly 400 affordable housing initiatives across all 67 counties in Pennsylvania
$73 million will fund 387 housing initiatives; 2024-25 bipartisan budget nearly doubles the Commonwealth's commitment to affordable housing by raising the PHARE Fund cap to $100 million per year by 2027
HARRISBURG, Pa., June 11, 2025 /PRNewswire/ -- The Pennsylvania Housing Finance Agency today announced recipients of a new round of funding for housing programs made available through the Pennsylvania Housing Affordability and Rehabilitation Enhancement fund. PHFA has identified 387 housing and community development initiatives in all 67 counties that will share a portion of the total $73 million in PHARE funding for fiscal year 2024-25. The PHARE fund is managed by PHFA.
"PHARE is one of the most effective tools we have to expand access to safe, affordable housing in every corner of the Commonwealth," said Governor Josh Shapiro. "That's why we've nearly doubled our investment in this program — because it works. Local communities know what they need, and PHARE gives them the resources to meet those needs, tackle the housing crisis, and help more Pennsylvanians stay in their homes. My budget proposal this year builds on that success by raising the PHARE cap to $110 million by 2028 — so we can build more homes, repair more aging properties, and deliver real results for the people of Pennsylvania."
Funding for these PHARE awards comes from two main sources. Since 2012, the program has received a portion of the impact fees collected from natural gas companies operating in the state with the goal of addressing the housing shortage caused by the impact of drilling. That is supplemented with funding provided by a portion of the realty transfer tax. The PHARE fund is often referred to as the state's Housing Trust Fund.
"I'm impressed each year with how well local organizations target PHARE dollars to address communities' housing needs," said PHFA Executive Director and CEO Robin Wiessmann. "We stress to applicants that their requests must demonstrate how PHARE money will be leveraged with other funding sources to make the largest housing impact possible, and that approach has significantly expanded PHARE's financial investment again this year."
PHFA anticipates that today's PHARE funding will assist Pennsylvania households through a variety of affordable housing efforts, including:
270 new, affordable housing units will be created with PHARE funds;
2,050 affordable housing units will be preserved/rehabilitated;
56 new single-family homes will be created;
140 housing units will be created or rehabilitated specifically for households in danger of homelessness;
122 potential new homebuyers will receive down payment and closing cost assistance;
More than 11,400 families/households will receive housing counseling and financial education; and
More than 13,900 families/households in danger of homelessness will receive housing assistance (rent, utility, transportation) through PHARE-funded programming.
PHFA staff report that at least $49 million (67%) of the $73 million allocated today will be used to fund housing projects benefiting households with incomes below 50% of the area median income.
A list of the proposals receiving PHARE funding is available at www.phfa.org/legislation/act105.aspx. See the bullet for "Funding Announcements."
Expanding PHARE to Deliver Safe, Affordable HousingGovernor Shapiro's 2024–25 bipartisan budget made major strides to address Pennsylvania's housing crisis — nearly doubling the Commonwealth's commitment to affordable housing by raising the PHARE Fund cap to $100 million per year by 2027. PHARE remains the state's most flexible and effective tool to build, preserve, and repair affordable housing across all 67 counties.
Building on that progress, the Governor's 2025–26 budget proposal invests an additional $10 million in PHARE and makes the largest overall investment in housing in Commonwealth history. It also advances efforts to keep Pennsylvanians in their homes — including $50 million for a new statewide housing repair fund, $10 million to help first-time homebuyers, and targeted eviction sealing reform. These investments, combined with the forthcoming statewide Housing Action Plan, reflect a bold and coordinated strategy to expand access to safe, affordable housing across Pennsylvania.
About PHFAThe Pennsylvania Housing Finance Agency works to provide affordable homeownership and rental housing options for older adults, low- and moderate-income families, and people with special housing needs. Through its carefully managed mortgage programs and investments in multifamily housing developments, PHFA also promotes economic development across the state. Since its creation by the legislature in 1972, it has generated more than $19.7 billion of funding for more than 205,147 single-family home mortgage loans, helped fund the construction of 110,284 rental units, distributed approximately $362 million to support local housing initiatives, and saved the homes of more than 51,400 families from foreclosure. PHFA programs and operations are funded primarily by the sale of securities and from fees paid by program users, not by public tax dollars. The agency is governed by a 14-member board.
Media contactScott Elliott717-649-6522 (cell)selliott@phfa.org
View original content:https://www.prnewswire.com/news-releases/phfa-announces-phare-funding-for-nearly-400-affordable-housing-initiatives-across-all-67-counties-in-pennsylvania-302479368.html
SOURCE Pennsylvania Housing Finance Agency
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis -- CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM). Key results continue to position AYVAKIT®/AYVAKYT® (avapritinib) as the durable standard of care across indolent and advanced SM, and highlight the real-world burden of the disease, reinforcing the importance of treating with a therapy that addresses the root cause of SM. These data will be reported at the 2025 European Hematology Association (EHA2025) Hybrid Congress, being held June 12 to 15 in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, being held June 13 to 16 in Glasgow, United Kingdom. "Our presentations feature large patient populations from the PIONEER, PATHFINDER and EXPLORER trials, with follow-up reaching up to five years in ISM and up to 6.5 years in advanced SM, reflecting both the favorable long-term benefits of AYVAKIT and the unprecedented datasets we have amassed over time," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "AYVAKIT has shown transformative clinical outcomes for patients across the spectrum of SM, including sustained disease control in ISM and prolonged survival in advanced SM. These compelling results have translated into real-world practice, with clinicians expanding their view of who is an appropriate candidate for disease-modifying therapy after positive AYVAKIT experiences, and treatment durations trending toward multiple years." PIONEER Three-Year Data: Durable Clinical Benefits and Consistent Safety Profile with Long-Term AYVAKIT Use in ISM As previously presented,1 AYVAKIT demonstrated robust improvements through 144 weeks in overall symptom and symptom domain measures (skin, gastrointestinal, neurocognitive) representative of real-world patient impacts. AYVAKIT showed a well-tolerated safety profile and a low discontinuation rate due to treatment-related adverse events (TRAEs; 3 percent) with a median of three years of exposure, and some patients out to five years on therapy. Common TRAEs included low-grade edemas, headache and nausea. In newly reported data, AYVAKIT showed sustained clinical benefits across quality-of-life measures that reflect general health status and are broadly recognized by allergists/immunologists, validating previously presented results from the disease-specific, Mastocytosis Quality of Life (MC-QoL) questionnaire. This data presentation follows the May 2025 online publication of PIONEER two-year efficacy and safety data in The Journal of Allergy and Clinical Immunology: In Practice. PATHFINDER/EXPLORER Multi-Year Data: Long-Term Survival Benefits of AYVAKIT in Advanced SM AYVAKIT showed prolonged overall survival (OS) in PATHFINDER and EXPLORER, when indirectly compared to real-world data for midostaurin from the German Registry on Disorders of Eosinophils and Mast Cells (GREM). AYVAKIT led to meaningful survival benefits in patients across all prognostic categories (low, intermediate and high risk), per the Revised Mutation-Adjusted Risk Score (MARS-R) – a new OS risk assessment tool for advanced SM. Conducted in collaboration with University Hospital Mannheim, the analyses validate the MARS-R tool's ability to assess OS risks in advanced SM patients treated with AYVAKIT or midostaurin, using clinical and genetic parameters. The MARS-R was developed to inform physician care decisions based on individual patient needs. PRISM Data: Substantial Disease Burden Across Broad Population of Patients with ISM PRISM is one of the largest studies characterizing the impact of SM from both patient and clinical perspectives. Across the spectrum of disease severity, patients with ISM experienced physical, social and emotional challenges that caused meaningful disruption to their daily lives. Patients reported a broad constellation of disease-related impacts, including limitations to physical activities, work/college and relationships; problems with pain/discomfort and anxiety/depression; and adjustments in their daily lives to avoid certain foods, extended sun exposure and smells. Data Presentations EHA2025 Congress Oral Presentation: The Revised Mutation-Adjusted Risk Score (MARS-R) for Predicting Overall Survival in Patients with Advanced Systemic Mastocytosis Treated with Midostaurin or Avapritinib (Abstract S216) Poster Presentation: Blood-Based Proteomics for Deeper Insights Into Indolent Systemic Mastocytosis: The PIONEER Trial Experience (Abstract PS1838) Poster Presentation: High Accuracy of Peripheral Blood Testing Using Machine Learning–Derived Predictive Models to Distinguish Advanced from Indolent Systemic Mastocytosis: Analysis of Avapritinib and Elenestinib Trial Data (Abstract PF1310) Publication-Only Abstract: Phase 2/3 HARBOR Study of Elenestinib in ISM: A Trial-in-Progress Update of Novel Endpoints and Biomarkers Aimed at Evaluating Disease Modification (Abstract PB3108) EAACI Congress 2025 Flash Talk Presentation: Favorable Benefit-Risk Profile of Avapritinib in Indolent Systemic Mastocytosis Is Maintained After 3 Years of Therapy: Longer-Term Analysis of the PIONEER Study (Abstract 000621) Flash Talk Presentation: The Socio-Emotional Impact of Indolent Systemic Mastocytosis: Insights from the PRISM Survey (Abstract 000488) Poster Presentation: The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients with Indolent Systemic Mastocytosis (Abstract 001121) Data presentations are being made available in the "Science―Publications and Presentations" section of the company's website at About Systemic Mastocytosis Systemic mastocytosis (SM) is a rare disease driven by the KIT D816V mutation in about 95 percent of cases. Uncontrolled proliferation and activation of mast cells result in chronic, severe and often unpredictable symptoms across multiple organ systems. The vast majority of those affected have indolent systemic mastocytosis (ISM). A broad range of symptoms, including anaphylaxis, maculopapular rash, pruritus, diarrhea, brain fog, fatigue and bone pain, frequently persist in patients with ISM despite treatment with multiple symptom-directed therapies. This burden of disease can lead to a profound, negative impact on quality of life. Patients often live in fear of severe, unexpected symptoms, have limited ability to work or perform daily activities, and isolate themselves to protect against unpredictable triggers. Until 2023, there were no approved therapies for the treatment of ISM. A minority of patients have advanced SM, which encompasses a group of high-risk SM subtypes including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL). In addition to mast cell activation symptoms, advanced SM is associated with organ damage due to mast cell infiltration and poor survival. About AYVAKIT AYVAKIT (avapritinib) is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) to treat the root cause of SM. It was FDA approved for the treatment of advanced SM in June 2021 and ISM in May 2023. It now is indicated in adults with ISM, adults with advanced SM, including ASM, SM-AHN and MCL, and adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. The medicine is approved in the EU as AYVAKYT for the treatment of adults with ISM with moderate to severe symptoms inadequately controlled on symptomatic treatment, adults with ASM, SM-AHN or MCL, after at least one systemic therapy, and adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation. The therapy is not recommended for the treatment of patients with low platelet counts (less than 50,000/µL). Globally, the medicine is approved for one or more indications in 16 countries, including China where it is marketed by CStone Pharmaceuticals, paying tiered percentage royalties on sales. Please click here to see the full U.S. Prescribing Information for AYVAKIT, and click here to see the European Summary of Product Characteristics for AYVAKYT. Important Safety Information Intracranial Hemorrhage — Serious intracranial hemorrhage (ICH) may occur with AYVAKIT treatment; fatal events occurred in <1% of patients. Overall, ICH (eg, subdural hematoma, ICH, and cerebral hemorrhage) occurred in 2.9% of 749 patients who received AYVAKIT in clinical trials. In Advanced SM patients who received AYVAKIT at 200 mg daily, ICH occurred in 2 of 75 patients (2.7%) who had platelet counts ≥50 x 109/L prior to initiation of therapy and in 3 of 80 patients (3.8%) regardless of platelet counts. In ISM patients, no events of ICH occurred in the 246 patients who received any dose of AYVAKIT in the PIONEER study. Monitor patients closely for risk factors of ICH which may include history of vascular aneurysm, ICH or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia. Symptoms of ICH may include headache, nausea, vomiting, vision changes, or altered mental status. Advise patients to seek immediate medical attention for signs or symptoms of ICH. Permanently discontinue AYVAKIT if ICH of any grade occurs. In Advanced SM patients, a platelet count must be performed prior to initiating therapy. AYVAKIT is not recommended in Advanced SM patients with platelet counts <50 x 109/L. Following treatment initiation, platelet counts must be performed every 2 weeks for the first 8 weeks. After 8 weeks of treatment, monitor platelet counts every 2 weeks or as clinically indicated based on platelet counts. Manage platelet counts of <50 x 109/L by treatment interruption or dose reduction. Cognitive Effects — Cognitive adverse reactions can occur in patients receiving AYVAKIT and occurred in 33% of 995 patients overall in patients who received AYVAKIT in clinical trials including: 28% of 148 Advanced SM patients (3% were Grade ≥3), and 7.8% of patients with ISM who received AYVAKIT + best supportive care (BSC) versus 7.0% of patients who received placebo + BSC (<1% were Grade 3). Depending on the severity and indication, withhold AYVAKIT and then resume at same dose or at a reduced dose upon improvement, or permanently discontinue. Photosensitivity — AYVAKIT may cause photosensitivity reactions. In all patients treated with AYVAKIT in clinical trials (n=1049), photosensitivity reactions occurred in 2.5% of patients. Advise patients to limit direct ultraviolet exposure during treatment with AYVAKIT and for one week after discontinuation of treatment. Embryo-Fetal Toxicity — AYVAKIT can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use an effective method of contraception during treatment with AYVAKIT and for 6 weeks after the final dose of AYVAKIT. Advise women not to breastfeed during treatment with AYVAKIT and for 2 weeks after the final dose. Adverse Reactions — The most common adverse reactions (≥20%) in patients with Advanced SM were edema, diarrhea, nausea, and fatigue/asthenia. The most common adverse reactions (≥10%) in patients with ISM were eye edema, dizziness, peripheral edema, and flushing. Drug Interactions — Avoid coadministration of AYVAKIT with strong or moderate CYP3A inhibitors. If coadministration with a moderate CYP3A inhibitor cannot be avoided in patients with Advanced SM, reduce dose of AYVAKIT. Avoid coadministration of AYVAKIT with strong or moderate CYP3A inducers. If contraception requires estrogen, limit ethinyl estradiol to ≤20 mcg unless a higher dose is necessary. To report suspected adverse reactions, contact Blueprint Medicines Corporation at 1-888-258-7768 or the FDA at 1-800-FDA-1088 or AYVAKIT is available in 25-mg, 50-mg, 100-mg and 200-mg tablets. Please click here to see the full U.S. Prescribing Information for AYVAKIT. About Blueprint Medicines Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with SM in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases and solid tumors. For more information, visit and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Blueprint Medicines' leadership role and its ability to transform treatment across the spectrum of SM, including sustained disease control in ISM and prolonged survival in advanced SM; AYVAKIT/AYVAKYT's position as the durable standard of care and clinicians' view of appropriate candidates and treatment duration; plans and expectations for Blueprint Medicines' current or future approved drugs and drug candidates; the potential benefits of any of Blueprint Medicines' current or future approved drugs or drug candidates in treating patients; and Blueprint Medicines' strategy, goals, business plans and focus. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to Blueprint Medicines' ability and plans in continuing to build out and expand a commercial infrastructure, and successfully launching, marketing and selling current or future approved products; Blueprint Medicines' ability to successfully expand the approved indications for AYVAKIT/AYVAKYT or obtain marketing approval for AYVAKIT/AYVAKYT in additional geographies in the future; the delay of any current or planned clinical trials or the development of Blueprint Medicines' current or future drug candidates; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the preclinical and clinical results for Blueprint Medicines' drug candidates, which may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines' ability to obtain, maintain and enforce patent and other intellectual property protection for AYVAKIT/AYVAKYT or any drug candidates it is developing; Blueprint Medicines' ability to successfully expand its operations, research platform and portfolio of therapeutic candidates, and the timing and costs thereof; the success of Blueprint Medicines' current and future collaborations, financing arrangements, partnerships or licensing arrangements; and the ability of the parties to consummate the proposed merger between Blueprint Medicines and Sanofi on the timeline anticipated or at all, including the occurrence of any event, change or other circumstance that could give rise to the termination of the merger. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' most recent Annual Report on Form 10-K, as supplemented by any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements. Footnote 1 Reported at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress Trademarks Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation. View original content to download multimedia: SOURCE Blueprint Medicines Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Dunhill Homes Announces $3,500 Closing Cost Incentive for Active Military at Skyview Community in Belton, TX
BELTON, Texas, June 12, 2025 /PRNewswire/ -- Dunhill Homes is proud to honor our nation's heroes by launching a new limited-time promotion at its Skyview community in Belton, Texas. Active military members who purchase a new Dunhill home at the Skyview Community are now eligible to receive $3,500 in closing cost assistance, helping make the path to homeownership even more achievable. This exclusive incentive reflects Dunhill's continued commitment to supporting those who serve, while offering quality-built homes in thoughtfully designed communities. Nestled in the scenic heart of Belton, Skyview blends small-town charm with modern comfort and quick access to Fort Hood, Lake Belton, and nearby cities like Temple and Killeen. "Skyview already offers incredible value and beautiful new homes," said Maghan, Marketing Manager at Dunhill Homes. "With this military-focused incentive, we're making it even easier for those actively serving to invest in their future and experience the lifestyle this community has to offer." Skyview features energy-efficient homes with open-concept floorplans, stylish finishes, and access to top-rated local amenities. The community is just minutes from outdoor recreation, local eateries, and shopping—making it ideal for families and individuals alike. To learn more about this limited-time military promotion or schedule a tour of Skyview, visit or contact your Dunhill Homes sales representative directly. About Dunhill HomesDunhill Homes® is a renowned, multi-award-winning homebuilder with a history of more than 15 years of excellence in homebuilding. Dunhill Homes is known for its quality craftsmanship and beautiful design and is dedicated to delivering an elevated living experience and exceptional value to homebuyers across a range of price points and different stages of life. For more information, visit It feels good to be home™ About Winchester Carlisle CompaniesWinchester Carlisle is a Dallas-based holding company that invests in diversified real estate businesses, and assets across Texas. The firm holds $385 million+ of investments across a broad range of real estate assets. With over 60 dedicated associates across a broad range of real estate enterprises, Winchester Carlisle brings local experience, national knowledge, in-depth expertise and uncompromising excellence to every business venture. For more information, visit Media Contact:Maghan PritchettMarketing ManagerDunhill Homes214-382-4860sales@ View original content to download multimedia: SOURCE Dunhill Homes
Yahoo
an hour ago
- Yahoo
/C O R R E C T I O N -- SAMBAZON/
In the news release, SAMBAZON® Launches New Pre-Topped, No-Sugar-Added Açaí & Smoothie Bowls for Ultimate Convenience, issued 02-Jun-2025 by SAMBAZON over PR Newswire, we are advised by the company that the headline should read "SAMBAZON® Launches New Pre-Topped Açaí & Smoothie Bowls for Ultimate Convenience" as originally issued inadvertently. The complete, corrected release follows: SAN CLEMENTE, Calif., June 2, 2025 /PRNewswire/ -- SAMBAZON®, the leader of Certified Organic and Fair Trade Açaí products, is excited to announce the launch of Fruit & Granola Topped Smoothie & Açaí Bowls. SAMBAZON's new set of pre-topped frozen açaí & smoothie bowls are designed for consumers who crave convenience without compromising on the smoothie bowl experience. These all-in-one bowls require no prep—simply thaw and enjoy! Building on the success of their original frozen bowls, which include toppings like granola and coconut flakes, and encourage customization with fresh fruit, SAMBAZON is now offering an effortless alternative with a no sugar added fruit blend and topped with a variety of frozen fruit in addition to gluten-free granolas. "We're always striving to offer an açaí option that suits every customer's preference and need," said Vicki Isip, Chief Marketing Officer of SAMBAZON. "While our existing bowls cater to those who love to customize, our new fruit topped bowls provide ultimate convenience. It's the perfect option for new customers looking to try an Açaí bowl without the prep work" The new line of açaí bowls comes in three delicious flavors: Açaí Berry Blend with Strawberry, Blueberry, Coconut & Granola Toppings Açaí Raspberry Blend with Diced Strawberry, Chocolate & Granola Toppings Mango Dragon Fruit Blend with Diced Mango, Pineapple, & Granola Toppings SAMBAZON's new bowls are currently available at Target, followed by Sprouts, and Publix this summer with more retailers expected later in the year. SAMBAZON remains committed to providing flavorful, convenient options for consumers who want to fuel their day with the Delicious Powers of Açaí. ABOUT SAMBAZON Founded in 2000, SAMBAZON, an acronym for Sustainable Management of the Brazilian Amazon, was the first company to introduce "certified Açaí" to the world, supplying organic and Fair Trade certified Açaí products such as Smoothie Packs, Ready to Eat Açaí Bowls, Juices, Energy drinks and Açaí Bites from a proprietary supply chain to ensure transparency from the "palm of the tree to the palm of your hand." For more information about SAMBAZON's mission and products, visit View original content to download multimedia: SOURCE SAMBAZON Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
